GLP-1R agonists clinical trial design must be improved to ease concerns
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, have garnered a lot of attention in the pharma industry and beyond.
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, have garnered a lot of attention in the pharma industry and beyond.